AssetMark’s ImmunityBio IBRX Stock Holding History
Bought
Maintained
Sold
Other funds holding IBRX
AssetMark's IBRX Position: Q3 2026 in Review
AssetMark opened a new position in ImmunityBio (IBRX) in Q3 2026: 5 shares worth $47. The stake represents ﹤0.01% of the portfolio and ranks #3720 among its holdings. This is a return to the name: AssetMark previously reported a position in IBRX as recently as Q1 2026.
AssetMark first reported a position in IBRX in Q2 2025 and has held it in 4 quarters since. The position peaked at $127 in Q2 2025. 321 funds tracked by Wall St. Rank hold IBRX as of Q3 2026.
- AssetMark held 5 shares of ImmunityBio worth $47 as of Q3 2026.
- ImmunityBio was a new AssetMark position in Q3 2026.
- ImmunityBio made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #3720 holding.
- AssetMark first reported a position in ImmunityBio in Q2 2025 and has held it in 4 quarters since.
- AssetMark's ImmunityBio position peaked at $127 in Q2 2025.
- 321 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2026.
Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.